Clinical Trial News and Research

RSS

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

4 Mar 2014

New AskRx version 1.0 enables patients to ask health and medication questions

RxWiki, Inc. announced today the launch of AskRx version 1.0, enabling patients to ask Digital Pharmacists™ health and medication questions.

4 Mar 2014

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check - for more than two years, in some cases - in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions.

4 Mar 2014

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.

4 Mar 2014

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

New findings point the way toward potentially more effective HIV vaccine

In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.

4 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to research from The University of Texas MD Anderson Cancer Center.

4 Mar 2014

Brief physical therapy improves symptoms, QoL in urinary incontinence

A 1-month programme of physical therapy results in significant improvements in quality of life among women with urinary incontinence, a clinical trial has found.

3 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.

3 Mar 2014

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

For people whose hands shake uncontrollably due to a medical condition, just eating can be a frustrating and embarrassing ordeal - enough to keep them from sharing a meal with others.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

Clinical Trial News and Research

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

New AskRx version 1.0 enables patients to ask health and medication questions

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

New findings point the way toward potentially more effective HIV vaccine

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

Brief physical therapy improves symptoms, QoL in urinary incontinence

Dendreon plans to make PROVENGE available in Europe

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer